Kodiak Sciences Inc (KOD) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $29.61: Quality below floor (2.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 5.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 26%; Below-average business quality; Negative price momentum.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF)... Read more
Sell if holding. Engine safety override at $29.61: Quality below floor (2.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 5.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 26%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.8/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 65d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-06-09Recent Developments — Kodiak Sciences Inc
Latest news
- NEWS This Pitney Bowes Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday — benzinga May 11, 2026 neutral
- NEWS Chardan Capital Upgrades Kodiak Sciences to Buy, Raises Price Target to $61 — benzinga May 11, 2026 positive
- NEWS Kodiak Sciences Q1 EPS $(0.94) Misses $(0.92) Estimate — benzinga May 7, 2026 negative
- NEWS Kodiak Sciences' KSI-101 MESI Data From Tertiary Care Uveitis Practice Consistent With Phase 1b APEX Study Results — benzinga May 1, 2026 positive
- NEWS Russell 2000 Rips To Record High — Here Are The Top Small Cap Gainers — benzinga Apr 17, 2026 positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $29.61: Quality below floor (2.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 5.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 26%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $28.65. Score 4.8/10, moderate confidence.
Take-profit target: $54.52 (+84.1% upside). Prior stop was $28.65. Stop-loss: $28.65.
Quality below floor (2.2 < 4.0).
Kodiak Sciences Inc trades at a P/E of N/A (forward -10.0). TrendMatrix value score: 9.0/10. Verdict: Sell.
11 analysts cover KOD with a consensus score of 4.1/5. Average price target: $63.
What does Kodiak Sciences Inc do?Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and...
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.